MoonLake Immunotherapeutics (MLTX) Accumulated Expenses (2020 - 2026)

MoonLake Immunotherapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $21.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 106.91% year-over-year to $21.8 million in Q1 2026; TTM through Mar 2026 was $21.8 million, a 106.91% increase from a year earlier, with the FY2025 full-year figure at $14.7 million, up 21.42% from the prior year.
• Accumulated Expenses rose to $21.8 million in Q1 2026 per MLTX's latest filing, from $14.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $21.8 million in Q1 2026 and bottomed at $30000.0 in Q1 2022.
• The 5-year median for Accumulated Expenses is $6.9 million (2023), against an average of $8.4 million.
• Across the five-year window, Accumulated Expenses sank 50.0% in 2022 and surged 10889.46% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $7.3 million in 2022, then slipped by 4.5% to $6.9 million in 2023, then jumped by 74.59% to $12.1 million in 2024, then climbed by 21.42% to $14.7 million in 2025, then jumped by 48.49% to $21.8 million in 2026.
• Per Business Quant, the three latest MLTX Accumulated Expenses figures stand at $21.8 million (Q1 2026), $14.7 million (Q4 2025), and $21.6 million (Q3 2025).